Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CELU

CELU - Celularity Inc. Stock Price, Fair Value and News

$1.25-0.04 (-3.10%)
Market Closed

54/100

CELU

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

54/100

CELU

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.41

Target 3M

$1.32

Target 6M

$1.35

CELU Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CELU Price Action

Last 30 days

4.2%

Last 90 days

-33.9%

Trailing 12 Months

-49.4%

CELU RSI Chart

CELU Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CELU Valuation

Market Cap

35.4M

Price/Earnings (Trailing)

-0.44

Price/Sales (Trailing)

0.87

EV/EBITDA

-0.71

Price/Free Cashflow

-6.7

CELU Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.41

Target 3M

$1.32

Target 6M

$1.35

CELU Fundamentals

CELU Revenue

Revenue (TTM)

40.6M

Rev. Growth (Yr)

-43.16%

Rev. Growth (Qtr)

-7.88%

CELU Earnings

Earnings (TTM)

-80.6M

Earnings Growth (Yr)

-43.35%

Earnings Growth (Qtr)

5.9%

CELU Profitability

Operating Margin

50.61%

EBT Margin

-198.75%

Return on Equity

401.35%

Return on Assets

-70.59%

Free Cashflow Yield

-14.91%

CELU Investor Care

Shares Dilution (1Y)

28.86%

Diluted EPS (TTM)

-3.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202551.0M44.6M40.6M0
202433.5M42.7M48.2M54.2M
202316.0M15.1M14.8M22.8M
202224.6M25.2M18.7M18.0M
202113.5M12.5M19.7M21.3M
202018.9M016.6M14.3M
201900021.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Celularity Inc.

CELU
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
 CEO
 WEBSITEcelularity.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES225

Celularity Inc. Frequently Asked Questions

CELU is the stock ticker symbol of Celularity Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Celularity Inc. is 35.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CELU's fair value in chart for subscribers.

The fair value guage provides a quick view whether CELU is over valued or under valued. Whether Celularity Inc. is cheap or expensive depends on the assumptions which impact Celularity Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CELU.

As of Wed Jan 28 2026, CELU's PE ratio (Price to Earnings) is -0.44 and Price to Sales (PS) ratio is 0.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CELU PE ratio will change depending on the future growth rate expectations of investors.